Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07767877 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07767877 · ClinicalTrials.gov record · last posted 2026-08-17

A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies

Name: A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies — clinical trial record (NCT07767877)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseNot specified

SponsorNovartis Pharmaceuticals

Started2026-08-31

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to describe real-world patient characteristics, treatment patterns, and adverse events associated with targeted therapies used in patients with complex vascular anomalies. The study will create an active registry for participating centers to enter data on patients with complex vascular anomalies being treated with sirolimus/everolimus (mTOR inhibitors), with/without trametinib (MEK inhibitor), or alpelisib (PIK3CA inhibitor). Tertiary care centers in the United States (US) that receive referrals for complex vascular anomaly cases and use Electronic Health Records (EHRs) will contribute patient medical chart reviews to this registry.

Trial Details

NCT Number	NCT07767877
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Vascular Anomalies
Enrollment	200 participants
Start Date	2026-08-31
Primary Completion	2027-10-30 (estimated)
Study Completion	2027-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-17